Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
- 19 November 2009
- journal article
- review article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 50 (12), 1916-1930
- https://doi.org/10.3109/10428190903207548
Abstract
The mammalian target of rapamycin (mTOR) pathway regulates translation of key proteins that contribute to the pathogenesis of advanced hematologic malignancies. Inhibitors of mTOR (temsirolimus, everolimus, and deforolimus) constitute a new class of antitumor agents, with potential for treatment of relapsed and/or refractory hematologic malignancies. Mantle cell lymphoma (MCL) was the first hematologic malignancy in which mTOR inhibition was explored as a treatment strategy, owing to its characteristic overexpression of cyclin D1, a G1 cyclin regulated by mTOR signaling. Temsirolimus and everolimus exhibited antitumor activity against relapsed, refractory disease in phase II studies. In a randomized phase III trial, once-weekly intravenous temsirolimus 175 mg for 3 weeks followed by 75 mg once weekly was recently shown to improve progression-free survival (p=0.0009) and objective response rate (p=0.0019) versus investigator's choice of therapy in relapsed or refractory MCL. Evidence of antitumor activity seen in early clinical trials for other non-Hodgkin lymphoma subtypes, multiple myeloma, and myeloid leukemias supports further studies of mTOR inhibitors, alone or in combination strategies, in these diseases. Overall, the clinical findings to date strengthen mTOR inhibition as a novel and promising strategy for the treatment of certain hematologic malignancies, particularly for MCL.Keywords
This publication has 67 references indexed in Scilit:
- Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndromeBritish Journal of Haematology, 2009
- A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced MalignanciesClinical Cancer Research, 2009
- Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and rapamycinMolecular Cancer Therapeutics, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008
- Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphomaBlood, 2008
- Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell LymphomaThe American Journal of Pathology, 2006
- Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood, 2006
- Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphomaBlood, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005